Correction to: Comparison of long-term antibody response to mRNA SARS-CoV-2 vaccine among peritoneal dialysis and hemodialysis patients

Einbinder, Yael; Hornik-Lurie, Tzipi; Cohen-Hagai, Keren; Goldman, Shira; Tanasiychuk, Tatiana; Nacasch, Naomi; Erez, Daniel; Magen, Sophie; Zitman‐Gal, Tali; Wiener-Well, Yonit; Frajewicki, Victor; Benchetrit, Sydney; Shavit, Linda; Bnaya, Alon

doi:10.1093/ndt/gfac141

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some, antibody titers were higher in PD compared with HD patients, 24 while in others, they were similar. 9 However, the kinetics of antibody titers over an entire year were not evaluated.…”

Section: Seropositivity Rates Among the Hd And Pd Groupsmentioning

confidence: 99%

“…The humoral immune response rate in the HD population after a two‐dose regimen of the COVID‐19 vaccination varies and has been reported to range from 30% to 95% 7,8 . Recently, we reported a relatively high humoral response (approximately 80%) to the Pfizer/BioNTech BNT162b2 mRNA vaccine 6 months after a two‐dose regimen, in a cohort of Israeli HD and peritoneal dialysis (PD) patients 9 . In July 2021, a third dose of BNT162b2 was approved in Israel to address waning immunity and emergence of the B.1.617.2 (Delta) variant of SARS‐CoV‐2.…”

Section: Introductionmentioning

confidence: 99%

“…7,8 Recently, we reported a relatively high humoral response (approximately 80%) to the Pfizer/BioNTech BNT162b2 mRNA vaccine 6 months after a two-dose regimen, in a cohort of Israeli HD and peritoneal dialysis (PD) patients. 9 In July 2021, a third dose of BNT162b2 was approved in Israel to address waning immunity and emergence of the B.1.617.2 (Delta) variant of SARS-CoV-2. A large population study reported a protective effect of the third dose of BNT162b2 mRNA vaccine against severe COVID-19 disease, compared to a two-dose regimen.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dialysis modality, humoral response to vaccine, and SARS‐CoV‐2 infection risk: Comparative prospective evaluation

Bnaya

Nacasch

Einbinder

et al. 2023

Seminars in Dialysis

Self Cite

View full text Add to dashboard Cite

BackgroundCOVID‐19 vaccinations have a central role in decreasing severe SARS‐CoV‐2 disease complications. This study investigated the long‐term humoral immune response to BNT162b2 vaccine among hemodialysis (HD) versus peritoneal dialysis (PD) patients, and their relative risk for COVID‐19 infection.MethodsThis prospective, observational study included maintenance HD and PD patients who had received at least two BNT162b2 vaccine doses. Levels of antibodies targeting SARS‐CoV‐2 spike protein were measured 6 and 12 months after the first vaccine dose, and 2–3 weeks after the third and fourth vaccine doses. Patients were divided according to dialysis modality (HD or PD). Humoral response was evaluated at different time points among different vaccine regimens (two vs. three vs. four doses of vaccine). An adjusted multivariate model was used to assess cumulative risk for SARS‐CoV‐2 infection.ResultsEighty‐seven HD and 36 PD patients were included. Among them, 106 (86%) received at least three vaccine doses. Both HD and PD patients demonstrated marked increases in humoral response 2–3 weeks after the third dose (mean anti‐S antibody increased from 452 ± 501 AU/mL to 19,556 ± 14,949 AU/mL, p < 0.001). By 6 months after the third dose, antibody titers had declined significantly (mean anti‐S antibody 9841 ± 10,493 AU/mL, p < 0.001). HD patients had higher risk for SARS‐CoV‐2 infection than PD patients (OR 4.4 [95% CI 1.4–13.6], p = 0.006). In multivariate analysis, the most important predictor for SARS‐CoV‐2 infection was dialysis modality.ConclusionThis study found a high antibody response rate after the third and fourth doses of BNT162b2 vaccine among dialysis patients. Hemodialysis as dialysis modality is an important predictor of COVID‐19 infection, despite similar humoral responses to vaccine in peritoneal dialysis.

show abstract

Section: Seropositivity Rates Among the Hd And Pd Groupsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dialysis modality, humoral response to vaccine, and SARS‐CoV‐2 infection risk: Comparative prospective evaluation

Bnaya

Nacasch

Einbinder

et al. 2023

Seminars in Dialysis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Neutralization assay or cellular assays will be considered in our future studies in order to improve the understanding of the impact of the immune response in hemodialysis patients. However, we did evaluate COVID-19 infection, and published the data separately [ 30 ], as well as the possible impact of different dialysis modality on humoral response to BNT162b2 vaccine [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Humoral Response to Hepatitis B and COVID-19 Vaccine among Maintenance Hemodialysis Patients

et al. 2022

View full text Add to dashboard Cite

Maintenance hemodialysis (MHD) patients have impaired immunological responses to pathogens and vaccines. In this study, we compared the humoral response to HBV and COVID-19 vaccines in a cohort of MHD patients. Demographic and clinical characteristics of vaccine responders and non-responders were also compared, and the association between the humoral responses to both vaccines was evaluated. The cohort included 94 MHD patients who were vaccinated at least once for HBV and twice for COVID-19. Among the 94 patients, 28 (29.8%) did not develop protective titers to HBV. Hypertension, coronary heart disease, and heart failure were more common in non-responders. Among MHD patients, 85% had positive IgG anti-spike SARS-CoV-2 levels 6 months after two doses of BNT162b2 (Pfizer/Biotech) vaccine. Age and immunosuppressive therapy were the main predictors of humoral response to COVID-19 vaccine. We did not find any association between non-responders to HBV and non-responders to COVID-19 vaccine. There was no difference in IgG anti-spike titers between HBV responders and non-responders (505 ± 644 vs. 504 ± 781, p = 0.9) Our results suggest that reduced humoral response to hepatitis B is not associated with reduced response to COVID-19 vaccine. Different risk-factors were associated with poor immune response to HBV and to COVID-19 vaccines.

show abstract

Outcomes of COVID-19 in peritoneal dialysis patients: A report by the European Renal Association COVID-19 Database

et al. 2023

View full text Add to dashboard Cite

Background: The clinical course of COVID-19 in peritoneal dialysis (PD) patients has so far only been analysed in relatively small, often single-centre case series. Therefore, we studied patient- and disease-related characteristics and outcomes of COVID-19 in a larger European cohort of PD patients. Methods: We used data from the European Renal Association COVID-19 Database (ERACODA) on PD and haemodialysis (HD) patients with COVID-19 (presentation between February 2020 and April 2021). Hazard ratios (HR) for mortality at 3 months were calculated using Cox proportional-hazards regression. In addition, we examined functional and mental health status among survivors at this time point as determined by their treating physician. Results: Of 216 PD patients with COVID-19, 80 (37%) were not hospitalised and 136 (63%) were hospitalised, of whom 19 (8.8%) were admitted to an intensive care unit. Mortality at 3 months for these subgroups was 18%, 40%, and 37%, respectively ( p = 0.0031). Compared with HD patients, PD patients had higher mortality (crude HR: 1.49; 95% CI: 1.33–1.66), even when adjusted for patient characteristics and disease severity (adjusted HR: 1.56; 95% CI: 1.39–1.75). Follow-up data on 67 of 146 patients who survived COVID-19 showed functional recovery to pre-COVID-19 levels in 52 (78%) and mental recovery in 58 patients (87%) at 3 months after the COVID-19 diagnosis. Conclusion: The mortality rate in the first 3 months after presentation with COVID-19 is high, especially among PD patients who were hospitalised. PD patients with COVID-19 had a higher mortality risk than HD patients. The majority of surviving patients recovered both functionally and mentally from COVID-19 within 3 months.

show abstract

Correction to: Comparison of long-term antibody response to mRNA SARS-CoV-2 vaccine among peritoneal dialysis and hemodialysis patients

Cited by 3 publications

References 0 publications

Dialysis modality, humoral response to vaccine, and SARS‐CoV‐2 infection risk: Comparative prospective evaluation

Dialysis modality, humoral response to vaccine, and SARS‐CoV‐2 infection risk: Comparative prospective evaluation

Humoral Response to Hepatitis B and COVID-19 Vaccine among Maintenance Hemodialysis Patients

Outcomes of COVID-19 in peritoneal dialysis patients: A report by the European Renal Association COVID-19 Database

Contact Info

Product

Resources

About